<DOC>
	<DOCNO>NCT02998775</DOCNO>
	<brief_summary>E7080-A001-010 multicenter , parallel-group study participant mild , moderate , severe hepatic renal impairment age- , gender- , smoke status-matched healthy participant . The primary objective study obtain plasma participant use vitro protein bind study .</brief_summary>
	<brief_title>Phase 0 Study Healthy , Hepatic Renal Impaired Subjects Obtain Plasma Lenvatinib Protein Binding</brief_title>
	<detailed_description>E7080-A001-010 multicenter , parallel-group study participant mild , moderate , severe hepatic renal impairment age- , gender- , smoke status-matched healthy participant . Approximately 6 participant degree ( mild , moderate , severe ) hepatic renal impairment enrol . Two cohort 8 healthy participant enrol . One cohort healthy participant match hepatic-impaired participant , whereas match renal-impaired participant . The study 2 phase . The Pre-study Phase consist Screening Period Baseline Period . The Study Phase consist 2-day Study Period . No lenvatinib administer study . The end study date last study visit last participant study . The following estimate provide : - From first participant last participant , study expect take approximately one year complete . - The maximum estimate duration study participant anticipate approximately 5 week .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Key Male Female Age , time Informed Consent : i. Hepatic Impairment Participants ( Including Matched Healthy Participants ) : 18 70 year old , inclusive ii . Renal Impairment Participants ( Including Matched Healthy Participants ) : 18 79 year old , inclusive Nonsmokers smoker smoke 10 cigarette per day Besides diabetes , appropriate , renal hepatic impairment , participant must history acute chronic clinically relevant disease condition , determine investigator . For participant hepatic impairment : Liver cirrhosis stable ; Platelet count &gt; 30,000 cells/millimeter cubed ( mm^3 ) ; Total score ChildPugh classification system 5 6 ( Group 1 , mild ) , 7 9 ( Group 2 , moderate ) , 10 15 ( Group 3 , severe ) For healthy participant : • Creatinine clearance ≥ 81 milliliter per minute ( mL/min ) For participant renal impairment : Must diagnosis renal impairment stable Must renal impairment follow category base creatinine clearance value : mild ( creatinine clearance , 50 80 mL/min ) , moderate ( creatinine clearance , 30 49 mL/min ) , severe ( creatinine clearance , 15 29 mL/min ) renal impairment Key Use new medication Human immunodeficiency virus ( HIV ) positive Presence acute active liver disease acute liver injury History significant cardiovascular impairment Positive drug alcohol test Weight loss gain &gt; 10 % prior Day 1 Receipt blood blood product donation blood blood product For participant hepatic impairment : History hepatic transplant , systemic lupus erythematosus , hepatic coma Received treatment interferon pegylated interferon Participants encephalopathy &gt; Grade 2 , sepsis , gastrointestinal bleeding ; esophageal varix &gt; Grade 2 , acute hepatic failure etiology , history surgical portosystemic shunt , renal impairment ( creatinine clearance &lt; 50 mL/min accord CockcroftGault formula ) , rapidly deteriorate hepatic function Systolic blood pressure ( SBP ) ≥ 160 millimeter mercury ( mmHg ) and/or diastolic blood pressure ( DBP ) ≥ 100 mmHg For healthy participant : • Hemoglobin level le 12.0 gram per deciliter ( g/dL ) For participant renal impairment : A history renal transplant SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg participant mild renal impairment ; SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg participant moderate severe renal impairment Significant bleeding diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>vitro protein bind</keyword>
	<keyword>hepatic impairment</keyword>
	<keyword>renal impairment</keyword>
</DOC>